伊伐布雷定联合双联抗血小板疗法对急性心肌梗死患者miR-423-5p、miR-499-5p表达的影响【摘要】目的:分析伊伐布雷定联合双联抗血小板疗法对急性心肌梗死患者miR-423-5p、miR-499-5p表达的影响。方法:本次总共抽取我院75例急性心肌梗死患者展开研究,年限截止为2019年8月-2021年12月。根据入院顺序采取奇偶数原则进行分组研究,对照组但给予双联抗血小板治疗(37例),研究组给予伊法布雷定联合双联抗血小板疗法治疗(38例),观察治疗后血脂水平、心功能状态以及miR-423-5p、miR-499-5p表达。结果:研究组血脂水平等改善均优于对照组(P<0.05);研究组心功能方面均与对照组存在统计学差异(P<0.05);两组miR-423-5p、miR-499-5p表达方面均较治疗前下调,且研究组改变大于对照组(P<0.05)。结论:伊伐布雷定联合双联抗血小板疗法对急性心肌梗死患者miR-423-5p、miR-499-5p表达有所改观,同时促进心功能及血脂水平改善。【关键词】伊伐布雷定;双联抗血小板疗法;急性心肌梗死;miR-423-5p;miR-499-5pEffects ofivabradine combined with dual antiplatelet therapy on the expression ofmiR-423-5p and miR-499-5p in patients with acute myocardial infarction【Abstract】Objective:To analyze the effect of ivabradine combined with dual antiplatelet therapy onthe expression of miR-423-5p and miR-499-5p in patients with acute myocardialinfarction. Methods: A total of 75 patients with acute myocardial infarction inour hospital were selected for the study, and the deadline was from August 2019to December 2021. According to the order of admission, the odd-even principlewas used for grouping studies. The control group was given dual antiplatelettherapy (37 cases), and the study group was given ifabradine combined with dualantiplatelet therapy (38 cases). Cardiac functional status and expression ofmiR-423-5p and miR-499-5p. Results: The improvement of total cholesterol (TC),triacylglycerol (TG) and low density lipoprotein (LDL-C) in the study groupwere better than those in the control group (P<0.05). LVESD), end-diastolicdiameter (LVEDD), and left ventricular ejection fraction (LVEF) weresignificantly different from those in the control group (P<0.05). It wasdown-regulated before treatment, and the change in the study group was greaterthan that in the control group (P<0.05). Conclusion: Ivabradine combinedwith dual antiplatelet therapy can improve the expression of miR-423-5p andmiR-499-5p in patients with acute myocardial infarction, and at the same timepromote the improvement of cardiac funct